Does adiponectin act as an antiangiogenic factor in B-cell chronic lymphocytic leukemia?

Stefano Molica, Giovanna Digiesi, Angelo Vacca, Rosanna Mirabelli, Katia Todoerti, Caterina Battaglia, Fortunato Morabito, Antonino Neri, Domenico Ribatti

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Angiogenesis is involved in the pathogenesis of B-cell chronic lymphocytic leukemia (CLL), and high microvascular density has been found in CLL to be associated with a poor prognosis. In this study, we assessed serum levels of adiponectin in 69 patients with Binet stage A B-CLL, and these values were retrospectively correlated with bone marrow (BM) microvessel area and serum levels of vascular endothelial growth factor (VEGF), fibroblast growth factor-2 (FGF-2), angiogenin, PECAM-1 (CD31), matrix metalloproteinase-9 (MMP-9), interleukin-8 (IL-8), syndecan-1, and the percentage of CD 38+ or ZAP- 70+ CLL cells. The positive correlation between serum levels of adiponectin and VEGF (P=.03) does not translate into an increase of the extent of BM angiogenesis (P=.404), FGF-2 (P=.348), angiogenin (P=.402), and CD31 (P=.248) serum concentrations. Accordingly, IL-8 (P=.175), syndecan-1 (P=.06), and MMP-9 (P=.144) circulating levels were not likely to reflect adiponectin concentration. Furthermore, patients with higher levels of adiponectin had a more favorable biological profile as defined by a lower number of both CD 38- (r=-0.294; P=.02) and ZAP- 70+ (r=-0.285; P=.04). Finally, we evaluated the presence of adiponectin in B-CLL cells at gene expression level. RMA intensity values for adiponectin gene transcript denote a homogeneous low expression in B-CLL cells, whereas VEGF transcript was highly expressed with a degree of interpatient variability. Overall, these data seem to indicate that adiponectin could be involved as an antiangiogenic factor in B-CLL.

Original languageEnglish
Article number287974
JournalAdvances in Hematology
Volume2009
DOIs
Publication statusPublished - 2009

Fingerprint

Adiponectin
B-Cell Chronic Lymphocytic Leukemia
Syndecan-1
Vascular Endothelial Growth Factor A
Matrix Metalloproteinase 9
Fibroblast Growth Factor 2
Serum
Interleukin-8
Bone Marrow
CD31 Antigens
Microvessels
Gene Expression
Genes

ASJC Scopus subject areas

  • Hematology

Cite this

Molica, S., Digiesi, G., Vacca, A., Mirabelli, R., Todoerti, K., Battaglia, C., ... Ribatti, D. (2009). Does adiponectin act as an antiangiogenic factor in B-cell chronic lymphocytic leukemia? Advances in Hematology, 2009, [287974]. https://doi.org/10.1155/2009/287974

Does adiponectin act as an antiangiogenic factor in B-cell chronic lymphocytic leukemia? / Molica, Stefano; Digiesi, Giovanna; Vacca, Angelo; Mirabelli, Rosanna; Todoerti, Katia; Battaglia, Caterina; Morabito, Fortunato; Neri, Antonino; Ribatti, Domenico.

In: Advances in Hematology, Vol. 2009, 287974, 2009.

Research output: Contribution to journalArticle

Molica, S, Digiesi, G, Vacca, A, Mirabelli, R, Todoerti, K, Battaglia, C, Morabito, F, Neri, A & Ribatti, D 2009, 'Does adiponectin act as an antiangiogenic factor in B-cell chronic lymphocytic leukemia?', Advances in Hematology, vol. 2009, 287974. https://doi.org/10.1155/2009/287974
Molica, Stefano ; Digiesi, Giovanna ; Vacca, Angelo ; Mirabelli, Rosanna ; Todoerti, Katia ; Battaglia, Caterina ; Morabito, Fortunato ; Neri, Antonino ; Ribatti, Domenico. / Does adiponectin act as an antiangiogenic factor in B-cell chronic lymphocytic leukemia?. In: Advances in Hematology. 2009 ; Vol. 2009.
@article{794479ad04544fba96cd5c26c0b7dab4,
title = "Does adiponectin act as an antiangiogenic factor in B-cell chronic lymphocytic leukemia?",
abstract = "Angiogenesis is involved in the pathogenesis of B-cell chronic lymphocytic leukemia (CLL), and high microvascular density has been found in CLL to be associated with a poor prognosis. In this study, we assessed serum levels of adiponectin in 69 patients with Binet stage A B-CLL, and these values were retrospectively correlated with bone marrow (BM) microvessel area and serum levels of vascular endothelial growth factor (VEGF), fibroblast growth factor-2 (FGF-2), angiogenin, PECAM-1 (CD31), matrix metalloproteinase-9 (MMP-9), interleukin-8 (IL-8), syndecan-1, and the percentage of CD 38+ or ZAP- 70+ CLL cells. The positive correlation between serum levels of adiponectin and VEGF (P=.03) does not translate into an increase of the extent of BM angiogenesis (P=.404), FGF-2 (P=.348), angiogenin (P=.402), and CD31 (P=.248) serum concentrations. Accordingly, IL-8 (P=.175), syndecan-1 (P=.06), and MMP-9 (P=.144) circulating levels were not likely to reflect adiponectin concentration. Furthermore, patients with higher levels of adiponectin had a more favorable biological profile as defined by a lower number of both CD 38- (r=-0.294; P=.02) and ZAP- 70+ (r=-0.285; P=.04). Finally, we evaluated the presence of adiponectin in B-CLL cells at gene expression level. RMA intensity values for adiponectin gene transcript denote a homogeneous low expression in B-CLL cells, whereas VEGF transcript was highly expressed with a degree of interpatient variability. Overall, these data seem to indicate that adiponectin could be involved as an antiangiogenic factor in B-CLL.",
author = "Stefano Molica and Giovanna Digiesi and Angelo Vacca and Rosanna Mirabelli and Katia Todoerti and Caterina Battaglia and Fortunato Morabito and Antonino Neri and Domenico Ribatti",
year = "2009",
doi = "10.1155/2009/287974",
language = "English",
volume = "2009",
journal = "Advances in Hematology",
issn = "1687-9104",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Does adiponectin act as an antiangiogenic factor in B-cell chronic lymphocytic leukemia?

AU - Molica, Stefano

AU - Digiesi, Giovanna

AU - Vacca, Angelo

AU - Mirabelli, Rosanna

AU - Todoerti, Katia

AU - Battaglia, Caterina

AU - Morabito, Fortunato

AU - Neri, Antonino

AU - Ribatti, Domenico

PY - 2009

Y1 - 2009

N2 - Angiogenesis is involved in the pathogenesis of B-cell chronic lymphocytic leukemia (CLL), and high microvascular density has been found in CLL to be associated with a poor prognosis. In this study, we assessed serum levels of adiponectin in 69 patients with Binet stage A B-CLL, and these values were retrospectively correlated with bone marrow (BM) microvessel area and serum levels of vascular endothelial growth factor (VEGF), fibroblast growth factor-2 (FGF-2), angiogenin, PECAM-1 (CD31), matrix metalloproteinase-9 (MMP-9), interleukin-8 (IL-8), syndecan-1, and the percentage of CD 38+ or ZAP- 70+ CLL cells. The positive correlation between serum levels of adiponectin and VEGF (P=.03) does not translate into an increase of the extent of BM angiogenesis (P=.404), FGF-2 (P=.348), angiogenin (P=.402), and CD31 (P=.248) serum concentrations. Accordingly, IL-8 (P=.175), syndecan-1 (P=.06), and MMP-9 (P=.144) circulating levels were not likely to reflect adiponectin concentration. Furthermore, patients with higher levels of adiponectin had a more favorable biological profile as defined by a lower number of both CD 38- (r=-0.294; P=.02) and ZAP- 70+ (r=-0.285; P=.04). Finally, we evaluated the presence of adiponectin in B-CLL cells at gene expression level. RMA intensity values for adiponectin gene transcript denote a homogeneous low expression in B-CLL cells, whereas VEGF transcript was highly expressed with a degree of interpatient variability. Overall, these data seem to indicate that adiponectin could be involved as an antiangiogenic factor in B-CLL.

AB - Angiogenesis is involved in the pathogenesis of B-cell chronic lymphocytic leukemia (CLL), and high microvascular density has been found in CLL to be associated with a poor prognosis. In this study, we assessed serum levels of adiponectin in 69 patients with Binet stage A B-CLL, and these values were retrospectively correlated with bone marrow (BM) microvessel area and serum levels of vascular endothelial growth factor (VEGF), fibroblast growth factor-2 (FGF-2), angiogenin, PECAM-1 (CD31), matrix metalloproteinase-9 (MMP-9), interleukin-8 (IL-8), syndecan-1, and the percentage of CD 38+ or ZAP- 70+ CLL cells. The positive correlation between serum levels of adiponectin and VEGF (P=.03) does not translate into an increase of the extent of BM angiogenesis (P=.404), FGF-2 (P=.348), angiogenin (P=.402), and CD31 (P=.248) serum concentrations. Accordingly, IL-8 (P=.175), syndecan-1 (P=.06), and MMP-9 (P=.144) circulating levels were not likely to reflect adiponectin concentration. Furthermore, patients with higher levels of adiponectin had a more favorable biological profile as defined by a lower number of both CD 38- (r=-0.294; P=.02) and ZAP- 70+ (r=-0.285; P=.04). Finally, we evaluated the presence of adiponectin in B-CLL cells at gene expression level. RMA intensity values for adiponectin gene transcript denote a homogeneous low expression in B-CLL cells, whereas VEGF transcript was highly expressed with a degree of interpatient variability. Overall, these data seem to indicate that adiponectin could be involved as an antiangiogenic factor in B-CLL.

UR - http://www.scopus.com/inward/record.url?scp=77953414615&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953414615&partnerID=8YFLogxK

U2 - 10.1155/2009/287974

DO - 10.1155/2009/287974

M3 - Article

C2 - 19960063

AN - SCOPUS:77953414615

VL - 2009

JO - Advances in Hematology

JF - Advances in Hematology

SN - 1687-9104

M1 - 287974

ER -